ADA检测中代表性混合基质选择的重要性

Originally published by Crystal Bio Solutions. Republished with company attribution. Original technical perspectives, references and source links are retained.

In immunogenicity testing, the pooled matrix (e.g., human serum, plasma in which antibodies or analytes are measured) serves both as the negative control and as the matrix for preparing positive control samples. Its quality directly impacts the screening cut point (SCP),a key parameter for distinguishing true positive from negative samples.

At Crystal Bio Solutions, our experts evaluated how different pooled matrices influence ADA assay performance and demonstrated that an unrepresentative pool can skew SCP values, leading to excessive false positives. By carefully selecting a more representative pooled matrix, we improved assay accuracy and ensured more meaningful immunogenicity results.

The Challenge of Using Unrepresentative Pooled Matrices

When an unrepresentative pooled matrix is used in ADA testing, the resulting SCP can fall abnormally low.

• In this case, Pool-A produced an SCP of 1.03, which would have incorrectly flagged many negative samples as positive.
• Such outcomes not only distort immunogenicity assessments but can also delay drug development by raising false safety concerns.

Establishing a Representative Pooled Matrix: A Case Study

Our experts compared multiple pooled matrices to identify one that better matched individual serum lots used in cut point determination.

• Pool-B showed signals consistent with the individual lots.
• As a result, the SCP shifted from 1.03 to 1.11, a more accurate value that better reflects true immunogenicity outcomes.

This simple but critical adjustment ensures that screening identifies positive samples appropriately while minimizing false positives.

Improved Accuracy and Reliability in ADA assay

The validated approach confirmed that:

• Pool-B was representative of individual samples, aligning closely with their baseline signals.
• The optimized SCP (1.11) allowed for more accurate ADA screening.
• False positives were reduced, improving the reliability of immunogenicity assessments in therapeutic protein development.

Why Pooled Matrix Selection Matters in ADA Assays

Immunogenicity evaluation is a cornerstone of biologic drug development. Using a poorly matched pooled matrix can undermine the accuracy of ADA assays, creating unnecessary hurdles in clinical development. By selecting a representative pooled matrix, our team helps ensure robust cut point determination, avoid false positives and provide confident decision-making in immunogenicity studies.

Key Takeaways

• Established the importance of using a representative pooled matrix in ADA assays
• Demonstrated that Pool-B provided signals consistent with individual serum lots
• Optimized the screening cut point from 1.03 to 1.11, improving accuracy
• Reduced false positives, delivering more reliable immunogenicity testing outcomes

📥📎 Access the case study

Read the original article and source figures